Top

Published in:

01-02-2014 | Topic Review

TET family proteins: new players in gliomas

Authors: Er-Bao Bian, Gang Zong, Yong-Sheng Xie, Xiao-Ming Meng, Cheng Huang, Jun Li, Bing Zhao

Published in: Journal of Neuro-Oncology | Issue 3/2014

Abstract

DNA methylation at the 5-position of cytosine (5mC) in the mammalian genome has emerged as a pivotal epigenetic event that plays important roles in development, aging and disease. The three members of the TET protein family, which convert 5mC to 5-hydroxymethylcytosine, has provided a potential mechanism resulting in DNA demethylation and maintaining cellular identity. Recent studies have shown that epigenetic modifications play a key role in the regulation of the molecular pathogenesis of gliomas. In this review we focus on demonstrating the TET proteins in DNA demethylation and transcriptional regulation of different target genes. In addition, we address the role of TET proteins in gliomas. This review will provide valuable insights into the potential targets of gliomas, and may open the possibility of novel therapeutic approaches to this fatal disease.

Williams SR, Joos BW, Parker JC, Parker JR (2008) Papillary glioneuronal tumor: a case report and review of the literature. Ann Clin Lab Sci 38:287–292PubMed

Joseph JV, Balasubramaniyan V, Walenkamp A, Kruyt FA (2013) TGF-beta as a therapeutic target in high grade gliomas: promises and challenges. Biochem Pharmacol 85:478–485PubMedCrossRef

Louis DN (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97–117PubMedCrossRef

Rychly B, Sidlova H, Danis D (2008) The 2007 World Health Organisation classification of tumours of the central nervous system, comparison with 2000 classification. Cesk Patol 44:35–36PubMed

Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14(Suppl 5):v1–v49PubMedCentralPubMedCrossRef

Goodenberger ML, Jenkins RB (2012) Genetics of adult glioma. Cancer Genet 205:613–621CrossRef

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralPubMedCrossRef

Zhu VF, Yang J, Lebrun DG, Li M (2012) Understanding the role of cytokines in glioblastoma multiforme pathogenesis. Cancer Lett 316:139–150PubMedCrossRef

Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152–2165PubMedCrossRef

10.

Yao XH, Liu Y, Chen K, Gong W, Liu MY, Bian XW et al (2011) Chemoattractant receptors as pharmacological targets for elimination of glioma stem-like cells. Int Immunopharmacol 11:1961–1966PubMedCentralPubMedCrossRef

11.

Ito S, D’Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y (2010) Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466:1129–1133PubMedCentralPubMedCrossRef

12.

Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–935PubMedCentralPubMedCrossRef

13.

Kriukiene E, Liutkeviciute Z, Klimasauskas S (2012) 5-Hydroxymethylcytosine the elusive epigenetic mark in mammalian DNA. Chem Soc Rev 41:6916–6930PubMedCentralPubMedCrossRef

14.

Tan L, Shi YG (2012) Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 139:1895–1902PubMedCrossRef

15.

He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q et al (2011) Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333:1303–1307PubMedCentralPubMedCrossRef

16.

Loenarz C, Schofield CJ (2009) Oxygenase catalyzed 5-methylcytosine hydroxylation. Chem Biol 16:580–583PubMedCrossRef

17.

Frauer C, Rottach A, Meilinger D, Bultmann S, Fellinger K, Hasenoder S et al (2011) Different binding properties and function of CXXC zinc finger domains in Dnmt1 and Tet1. PLoS One 6:e16627PubMedCentralPubMedCrossRef

18.

Iyer LM, Tahiliani M, Rao A, Aravind L (2009) Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8:1698–1710PubMedCentralPubMedCrossRef

19.

Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M et al (2010) Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol 17:62–68PubMedCentralPubMedCrossRef

20.

Song J, Rechkoblit O, Bestor TH, Patel DJ (2011) Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 331:1036–1040PubMedCrossRef

21.

Xu C, Bian C, Lam R, Dong A, Min J (2011) The structural basis for selective binding of non-methylated CpG islands by the CFP1 CXXC domain. Nat Commun 2:227PubMedCentralPubMedCrossRef

22.

Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J et al (2011) Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 42:451–464PubMedCentralPubMedCrossRef

23.

Zhang H, Zhang X, Clark E, Mulcahey M, Huang S, Shi YG (2010) TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res 20:1390–1393PubMedCrossRef

24.

Kim JK, Samaranayake M, Pradhan S (2009) Epigenetic mechanisms in mammals. Cell Mol Life Sci 66:596–612PubMedCentralPubMedCrossRef

25.

Langemeijer SM, Aslanyan MG, Jansen JH (2009) TET proteins in malignant hematopoiesis. Cell Cycle 8:4044–4048PubMedCrossRef

26.

Hino S, Kishida S, Michiue T, Fukui A, Sakamoto I, Takada S et al (2001) Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol Cell Biol 21:330–342PubMedCentralPubMedCrossRef

27.

Kojima T, Shimazui T, Hinotsu S, Joraku A, Oikawa T, Kawai K et al (2009) Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene 28:297–305PubMedCrossRef

28.

Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2(Suppl 1):S4–S11PubMedCrossRef

29.

Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428PubMedCrossRef

30.

Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A et al (2011) Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146:67–79PubMedCentralPubMedCrossRef

31.

Inoue A, Zhang Y (2011) Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science 334:194PubMedCentralPubMedCrossRef

32.

Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA et al (2011) Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333:1300–1303PubMedCentralPubMedCrossRef

33.

Guo JU, Su Y, Zhong C, Ming GL, Song H (2011) Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145:423–434PubMedCentralPubMedCrossRef

34.

Wu SC, Zhang Y (2010) Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 11:607–620PubMedCentralPubMedCrossRef

35.

Otani J, Arita K, Kato T, Kinoshita M, Kimura H, Suetake I et al (2013) Structural basis of the versatile DNA recognition ability of the methyl-CpG binding domain of methyl-CpG binding domain protein 4. J Biol Chem 288:6351–6362PubMedCrossRef

36.

Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J et al (2011) TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473:343–348PubMedCentralPubMedCrossRef

37.

Wu H, Zhang Y (2011) Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 25:2436–2452PubMedCrossRef

38.

Wu H, D’Alessio AC, Ito S, Xia K, Wang Z, Cui K et al (2011) Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 473:389–393PubMedCentralPubMedCrossRef

39.

Wu H, D’Alessio AC, Ito S, Wang Z, Cui K, Zhao K et al (2011) Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev 25:679–684PubMedCrossRef

40.

Kreppel LK, Blomberg MA, Hart GW (1997) Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem 272:9308–9315PubMedCrossRef

41.

Shi FT, Kim H, Lu W, He Q, Liu D, Goodell MA et al (2013) Ten-eleven translocation 1 (Tet1) is regulated by O-linked N-acetylglucosamine transferase (Ogt) for target gene repression in mouse embryonic stem cells. J Biol Chem 288:20776–20784PubMedCrossRef

42.

Vella P, Scelfo A, Jammula S, Chiacchiera F, Williams K, Cuomo A et al (2013) Tet proteins connect the O-linked N-acetylglucosamine transferase Ogt to chromatin in embryonic stem cells. Mol Cell 49:645–656PubMedCrossRef

43.

Freudenberg JM, Ghosh S, Lackford BL, Yellaboina S, Zheng X, Li R et al (2012) Acute depletion of Tet1-dependent 5-hydroxymethylcytosine levels impairs LIF/Stat3 signaling and results in loss of embryonic stem cell identity. Nucleic Acids Res 40:3364–3377PubMedCentralPubMedCrossRef

44.

Deplus R, Delatte B, Schwinn MK, Defrance M, Mendez J, Murphy N et al (2013) TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J 32:645–655PubMedCrossRef

45.

Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33(Suppl):245–254PubMedCrossRef

46.

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812PubMedCentralPubMedCrossRef

47.

Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD et al (2009) Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 3:39–52PubMedCentralPubMed

48.

Guo C, Pirozzi CJ, Lopez GY, Yan H (2011) Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol 24:648–652PubMedCentralPubMedCrossRef

49.

Yen KE, Bittinger MA, Su SM, Fantin VR (2010) Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29:6409–6417PubMedCrossRef

50.

Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30PubMedCentralPubMedCrossRef

51.

Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–567PubMedCrossRef

52.

Guilhamon P, Eskandarpour M, Halai D, Wilson GA, Feber A, Teschendorff AE et al (2013) Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nat Commun 4:2166PubMedCentralPubMedCrossRef

53.

Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al (2009) Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23:1343–1345PubMedCrossRef

54.

Parsons DW, Jones S, Zhang X et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068CrossRef

55.

Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S et al (2012) Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:484–488PubMedCentralPubMedCrossRef

56.

Kim YH, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M et al (2011) TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 64:850–852PubMedCrossRef

57.

Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839–843PubMedCentralPubMedCrossRef

58.

Konstandin N, Bultmann S, Szwagierczak A, Dufour A, Ksienzyk B, Schneider F et al (2011) Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 25:1649–1652PubMedCrossRef

59.

Muller T, Gessi M, Waha A, Isselstein LJ, Luxen D, Freihoff D et al (2012) Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am J Pathol 181:675–683PubMedCrossRef

60.

Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG (2012) Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One 7:e41036PubMedCentralPubMedCrossRef

61.

Pfaffeneder T, Hackner B, Truss M, Munzel M, Muller M, Deiml CA et al (2011) The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew Chem Int Ed Engl 50:7008–7012PubMedCrossRef

62.

Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G et al (2011) 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 71:7360–7365PubMedCentralPubMedCrossRef

63.

Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Munzel M et al (2012) Low values of 5-hydroxymethylcytosine (5hmC), the “sixth base”, are associated with anaplasia in human brain tumors. Int J Cancer 131:1577–1590PubMedCrossRef

64.

Kulis M, Esteller M (2010) DNA methylation and cancer. Adv Genet 70:27–56

65.

Taberlay PC, Jones PA (2011) DNA methylation and cancer. Prog Drug Res 67:1–23PubMed

66.

Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH et al (2012) TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep 2:568–579PubMedCrossRef

67.

Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J et al (2013) Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32:663–669PubMedCentralPubMedCrossRef

68.

Huang N, Tan L, Xue Z, Cang J, Wang H (2012) Reduction of DNA hydroxymethylation in the mouse kidney insulted by ischemia reperfusion. Biochem Biophys Res Commun 422:697–702PubMedCrossRef

69.

Lam P, Sian Lim K, Mei Wang S, Hui KM (2005) A microarray study to characterize the molecular mechanism of TIMP-3-mediated tumor rejection. Mol Ther 12:144–152PubMedCrossRef

70.

Muhlisch J, Bajanowski T, Rickert CH, Roggendorf W, Wurthwein G, Jurgens H et al (2007) Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurooncol 83:17–29PubMedCrossRef

Title: TET family proteins: new players in gliomas
Authors: Er-Bao Bian
Gang Zong
Yong-Sheng Xie
Xiao-Ming Meng
Cheng Huang
Jun Li
Bing Zhao
Publication date: 01-02-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1328-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

TET family proteins: new players in gliomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Insulin like growth factor binding protein 4 promotes GBM progression and regulates key factors involved in EMT and invasion

Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells

Adults with CNS primitive neuroectodermal tumors/pineoblastomas: results of multimodal treatment according to the pediatric HIT 2000 protocol

A rare infectious presentation of a temporal bone meningioma

Gene expression profiling analysis reveals that DLG3 is down-regulated in glioblastoma

Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections